ABCG2 and cancer: Recognizing that inducing a transient downregulation in the protein expression of ABCB1 and ABCG2 through drug treatment could also restore sensitivity to anticancer drugs in multidrug-resistant cancer cells [21,22], we investigated how furmonertinib influences the protein expression of ABCB1 and ABCG2 in multidrug-resistant cancer cells.